TY - JOUR T1 - A <em>katG</em> 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01696-2017 VL - 50 IS - 4 SP - 1701696 AU - Einar Heldal Y1 - 2017/10/01 UR - http://erj.ersjournals.com/content/50/4/1701696.abstract N2 - We thank D. Chesov and co-workers for sharing data on isoniazid-resistant strains in Moldova as a comment on our paper on shorter regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB) [1]. In strains from MDR-TB patients, a high proportion (88%) had a mutation in the katG gene at position 315, results which “…strongly suggest that high-dose isoniazid should not be part of a standardised treatment regimen for patients with MDR-TB…”, based on the “…general consensus that high-level isoniazid resistance due to a mutation in the katG gene at position 315 cannot be overcome by high-dose isoniazid treatment…”. They refer to a recent TBNET/RESIST-TB consensus statement [2] which says that molecular testing for isoniazid resistance should be done since “…it offers the possibility to add INH to a second-line drug regimen in the absence of a katG 315 mutation…”.A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis http://ow.ly/18cd30fiJfs ER -